PAI-1 sirna-lipid nanoparticles

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 2 countries

Funders: American Heart Association and 6 more

Animals1

Outcomes

PAI-1

downin mice1−90% knockdown

1 study

PAI-1 sirna-lipid nanoparticles decrease PAI-1 in mice (90% knockdown).
“One dose of siPAI-1 resulted in 90% knockdown of plasma PAI-1 and lasted 10 days after administration with no overt toxicity.”
Animalsin vivoone dose10 days
Silencing of PAI-1 using siRNA-lipid nanoparticles reduces thrombosis and prolongs life span in murine models
Blood26 Jan 2026

Latest

1 in 12 months

Blood26 Jan

Silencing of PAI-1 using siRNA-lipid nanoparticles reduces thrombosis and prolongs life span in murine models

Experiments in miceThrombosis

Paper

PAI-1 sirna-lipid nanoparticles

Outcomes

Latest

Silencing of PAI-1 using siRNA-lipid nanoparticles reduces thrombosis and prolongs life span in murine models

Related